HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Submit a Letter to Editor Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Scherr, M. Articles by Engels, J. W. Search for Related Content PubMed PubMed Citation Articles by Scherr, M. Articles by Engels, J. W. Social Bookmarking                      What's this?

Volume 272, Number 22, Issue of May 30, 1997 pp. 14304-14313
©1997 by The American Society for Biochemistry and Molecular Biology, Inc.

Specific Hammerhead Ribozyme-mediated Cleavage of Mutant N-ras mRNA in Vitro and ex Vivo
OLIGORIBONUCLEOTIDES AS THERAPEUTIC AGENTS

(Received for publication, November 19, 1996, and in revised form, February 24, 1997)

Michaela Scherr , Manuel Grez , Arnold Ganser ^§ and Joachim W. Engels

From the Institut für Organische Chemie, Johann Wolfgang Goethe-Universität, D-60439 Frankfurt am Main,  Georg-Speyer-Haus, Abteilung Molekulare Virologie III, 60596 Frankfurt am Main, Germany, and ^§ Medizinische Hochschule, Abteilung Hämatologie und Onkologie, 30625 Hannover, Germany

Two hammerhead ribozymes targeted to point mutations in codon 13 of the N-ras oncogene were synthesized and their catalytic activity and substrate specificity evaluated in vitro and ex vivo. In vitro studies showed that these ribozymes were specific for the oncogenic form of N-ras, since cleavage was observed only in a 849-nucleotide-long transcript containing mutant but not wild-type N-ras sequences. For the ex vivo studies, the ribozymes were 2-modified to protect them against degradation by nucleases. 2-Fluoro-2-deoxyuridine/cytidine-substituted ribozymes were nearly as active as their unmodified counterparts, but had a prolonged stability in cell culture supernatant containing fetal calf serum. The stability of the modified ribozymes increased by introduction of terminal phosphorothioates groups without significant influence in their catalytic efficiency. A sensitive assay based on the use of N-ras/luciferase fusion genes as a reporter system was established to detect ribozyme-mediated cleavage in HeLa cells. A reduction of nearly 60% in luciferase activity was observed in cells expressing mutant but not wild-type N-ras/luciferase fusion transcripts. Moreover, cleavage of N-ras transcripts in HeLa cells was directly confirmed by a semi-quantitative RT-PCR assay.

CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				R. HUHN, M. S. STAEGE, M. HESSE, B. LIEBIG, and S. E.G. BURDACH Cleavage of the Ewing Tumour-specific EWSR1-FLI1 mRNA by Hammerhead Ribozymes Anticancer Res, June 1, 2009; 29(6): 1901 - 1908. [Abstract] [Full Text] [PDF]

				S. P. lyngstadaas Synthetic Hammerhead Ribozymes as Tools in Gene Expression Critical Reviews in Oral Biology & Medicine, January 1, 2001; 12(6): 469 - 478. [Abstract] [Full Text] [PDF]

				B. Bramlage, E. Luzi, and F. Eckstein HIV-1 LTR as a target for synthetic ribozyme-mediated inhibition of gene expression: site selection and inhibition in cell culture Nucleic Acids Res., November 1, 2000; 28(21): 4059 - 4067. [Abstract] [Full Text] [PDF]

				M. Amarzguioui, G. Brede, E. Babaie, M. Grotli, B. Sproat, and H. Prydz Secondary structure prediction and in vitro accessibility of mRNA as tools in the selection of target sites for ribozymes Nucleic Acids Res., November 1, 2000; 28(21): 4113 - 4124. [Abstract] [Full Text] [PDF]

				P. A. Dawson and J. C. Marini Hammerhead ribozymes selectively suppress mutant type I collagen mRNA in osteogenesis imperfecta fibroblasts Nucleic Acids Res., October 15, 2000; 28(20): 4013 - 4020. [Abstract] [Full Text] [PDF]

				L. Q. Sun, M. J. Cairns, E. G. Saravolac, A. Baker, and W. L. Gerlach Catalytic Nucleic Acids: From Lab to Applications Pharmacol. Rev., September 1, 2000; 52(3): 325 - 348. [Abstract] [Full Text] [PDF]

				M. Scherr, J. J. Rossi, G. Sczakiel, and V. Patzel RNA accessibility prediction: a theoretical approach is consistent with experimental studies in cell extracts Nucleic Acids Res., July 1, 2000; 28(13): 2455 - 2461. [Abstract] [Full Text] [PDF]

				I. Kitajima, N. Hanyu, Y. Soejima, R. Hirano, S. Arahira, S. Yamaoka, R. Yamada, I. Maruyama, and Y. Kaneda Efficient Transfer of Synthetic Ribozymes into Cells Using Hemagglutinating Virus of Japan (HVJ)-Cationic Liposomes. APPLICATION FOR RIBOZYMES THAT TARGET HUMAN T-CELL LEUKEMIA VIRUS TYPE I tax/rex mRNA J. Biol. Chem., October 24, 1997; 272(43): 27099 - 27106. [Abstract] [Full Text] [PDF]